GenoFlex mass spectrometer

	Next higher product group	MALDI-TOF mass spectrometer
	Status	2001-11-05
	Organisation	Bruker Daltonics Inc.
	Group	Bruker Corporation (Group)

Sequenom, Inc.. (11/5/01). "Press Release: Sequenom and Bruker Daltonics to Develop Medium-throughput Genotyping System Based on MALDI-TOF Mass Spectrometry. GenoFlex Product to Complement Sequenom's High-Throughput MassARRAY Platform". San Diego & Bille

SEQUENOM(TM), Inc. (Nasdaq: SQNM) and Bruker Daltonics Inc. (Nasdaq: BDAL) today announced an agreement to develop a next-generation bench-top mass spectrometer to be included in SEQUENOM'S MassARRAY(TM) genotyping system. Bruker Daltonics will develop the new GenoFlex for SEQUENOM based on the proven method of MALDI-TOF mass spectrometry, the same technology employed in SEQUENOM's existing high-throughput MassARRAY platform that also includes Bruker instrumentation. SEQUENOM will offer the GenoFlex system as a medium throughput (MT) model to expand the Company's genotyping market coverage over a broader range of potential customers.

"This agreement is a result of the strong working relationship we enjoy with Bruker Daltonics," said Toni Schuh, Ph.D., SEQUENOM's President and Chief Executive Officer. "Our existing MassARRAY customers have come to rely on the quality instrumentation provided by Bruker Daltonics. The GenoFlex MT or medium throughput instrument is expected to build on the success of our MassARRAY system by providing the same reliable and accurate genotyping results provided by our high throughput product offering. We expect the addition of the GenoFlex MT to provide SEQUENOM with access to a broader market segment of customers which may be in the earlier stages of their ramp up in throughput requirements for genotyping, but are still interested in the features of our MassARRAY product line."

Frank Laukien, Ph.D., President and CEO of Bruker Daltonics, commented, "We are very impressed with SEQUENOM's success in establishing genotyping by MALDI-TOF mass spectrometry as a direct, highly accurate and high-throughput standard method, particularly for human pharmacogenomics and research in molecular diagnostics. Therefore, we are very pleased to expand our long- standing collaboration with SEQUENOM to the medium-throughput genotyping market."

About Bruker Daltonics

Bruker Daltonics is a leading provider of innovative life science tools based on mass spectrometry. Its substantial investment in research and development allows it to design, manufacture and market a broad array of products intended to meet the rapidly growing needs of a diverse customer base, including pharmaceutical companies, biotechnology companies, proteomics companies, molecular diagnostics companies, academic institutions and government agencies. Bruker Daltonics has diverse technology platforms that integrate automated sample preparation and clean-up, advanced front-end AnchorChip(TM) MALDI targets and API source technology with cutting-edge proprietary MALDI-TOF, MALDI-TOF/TOF, ESI-TOF, ESI-Q-q-TOF, ion trap and FTMS mass analyzers, as well as analysis and bioinformatics software. Bruker Daltonics is also a worldwide leader in supplying mass spectrometry-based systems for substance detection and pathogen identification in security, defense and anti-terrorism applications. Further information is available at: http://www.bdal.com .

About SEQUENOM

SEQUENOM is a discovery genetics company with the tools, information and strategies for determining the medical impact of genes and genetic variations. Utilizing a novel population genetics approach, SEQUENOM is systematically identifying potential disease-related genes that affect significant portions of the overall population. This approach is possible due to the pinpoint accuracy and unique specificity of the Company's MassARRAY system. By focusing on disease genes with a broad population impact, SEQUENOM expects to play an important role in bringing new therapeutic products to the market while maximizing the return on drug development. SEQUENOM completed its merger with Gemini Genomics plc, a clinical genomics company, in September 2001.

Except for the historical information contained herein, the matters set forth in this press release, including those statements related to building upon the success of SEQUENOM's MassARRAY system, the reliability and accuracy of the GenoFlex MT, the expectation of access to a broader market segment of customers, the systematic identification of disease-related genes and SEQUENOM's role in the development of new therapeutic products and maximization of drug development returns are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties inherent in drug discovery, development and commercialization efforts, the risks and uncertainties associated with SEQUENOM's technologies and approaches to drug discovery, development and commercialization and those of its collaborative partners and competitors, and other risks detailed from time to time in SEQUENOM's SEC reports, including SEQUENOM's Annual Report on Form 10-K for the year ended December 31, 2000 and most recent Quarterly Report on Form 10-Q and Gemini Genomics' Annual Report on Form 20-F for the year ended March 31, 2001 and quarterly report on Form 6- K filed with the SEC on August 14, 2001. These forward-looking statements speak only as of the date hereof. SEQUENOM disclaims any intent or obligation to update these forward-looking statements.

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements of Bruker Daltonics as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.

For further information, please contact

Abigail Devine, APR, Investor Relations of SEQUENOM, Inc., +1-858-202-9032, adevine@sequenom.com;

or
Michael Willett, Investor Relations Officer of Bruker Daltonics Inc., +1-978-663-3660, ext.1411, michael.willett@bdal.com;

or

Emily Poe of Noonan/Russo Communications, +1-212-696-4455, ext. 221, e.poe@noonanrusso.com.

Record changed: 2011-11-25

Follow Us!

Top News

Upcoming Events

Associations

Partners

GenoFlex mass spectrometer

Sequenom, Inc.. (11/5/01). "Press Release: Sequenom and Bruker Daltonics to Develop Medium-throughput Genotyping System Based on MALDI-TOF Mass Spectrometry. GenoFlex Product to Complement Sequenom's High-Throughput MassARRAY Platform". San Diego & Bille

More documents for MALDI-TOF mass spectrometer